Adagene
ADAG | NASDAQ
$1.60
-$0.11 (-6.43%)
At close: Nov 16, 2026, 4:00 PM ET
$1.60
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-6.43%
(1D)No price chart data available for 1D timeframe.
Rating
49.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #298/1021 (Top 29%)
Key Statistics
Market Data
Market Cap $72.47M
1D Range
1.42 1.85
52W Range
1.42 4.78
Valuation (TTM)
PE -3.40
PB 0.68
EV/EBITDA 2.26
Valuation (NTM)
Forward PE N/A
Forward PEG -0.41
Price Target $8.00
Cash Flow
FCF Yield -26.9%
SBC Adj. FCF Yield -26.9%
SBC Impact N/A
Margins
Gross Margin 94.2%
Operating Margin -240.3%
FCF Margin -209.0%
Growth (CAGR)
Revenue 3Y | 5Y -21.3% |
63.8%
Dil EPS 3Y | 5Y 36.4% |
41.1%
FCF 3Y | 5Y -83.5% |
-50.0%
Returns
ROA -15.4%
ROE -29.1%
ROIC -19.6%
Financial Health
Net Cash
$122.01M
Current Ratio 5.02
Interest Coverage -78.34
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineere...
Sector Healthcare
Industry Biotechnology
Employees 128
IPO Date Feb 9, 2021
Website www.adagene.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$8.00
Upside
+400.00%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ADAG